logo-loader

NetScientific says latest data shows “invaluable potential” of portfolio company Wanda’s technology

Published: 03:07 21 May 2018 EDT

doctor in hospital
NetScientific holds a 62% stake in Wanda

Netscientific PLC (LON:NSCI) boss Francois Martelet has heaped praise on portfolio company Wanda after new data confirmed the benefits of its technology.

Wanda has developed a system which continuously assesses patients in real time and can detect adverse events up to a week before they happen.

READ: NSCI looking for hard exits as portfolio matures

By using that technology, the number of hospital readmissions for congestive heart failure patients – a patient population with a typically high readmission rate – almost halved (46% reduction).

There are currently 576 patients enrolled on the programme, but Martelet, who is also chairman of Wanda, thinks the latest figures provide a “strong rationale” for rolling out the system to more people.

“The data are impressive as patients with congestive heart failure typically have a very high re-admission rate,” said Martelet.

“This demonstrates the invaluable potential Wanda's technology has in streamlining care and improving patient outcomes.”

He added: “We are entering a new digital era of healthcare in which we firmly believe Wanda can play a pivotal role, and we are very pleased to see the collaboration with HRS working so well.”

NetScientific holds a 62% stake in Wanda.

Shares rose 12.6% to 49p at the opening bell on Monday.

--Updates for share price--

NetScientific portfolio company PDS Biotechnology to advance lead candidate...

Frank Bedu-Addo, president and CEO of PDS Biotechnology Corporation (NASDAQ:PDSB), a NetScientific PLC (AIM:NSCI) portfolio company, tells Proactive's Stephen Gunnion that a recent US$35mln debt financing agreement provides the financial resources necessary to advance the company's clinical...

on 09/20/2022